Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults

Eline Boon, Winette T. A. van der Graaf, Hans Gelderblom, Margot E. T. Tesselaar, Robert J. J. van Es, Sjoukje F. Oosting, Remco de Bree, Esther van Meerten, Ann Hoeben, Ludi E. Smeele, Stefan M. Willems, Max J. H. Witjes, Jan Buter, Robert J. Baatenburg de Jong, Uta E. Flucke, Petronella G. M. Peer, Judith V. M. G. Bovee, Carla M. L. Van Herpen*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Background: There is an ongoing debate about the value of (neo‐)adjuvant chemotherapy in high‐ and intermediate‐grade osteosarcoma of the head and neck.
Methods: All records of patients older than 16 years diagnosed with osteosarcoma of the head and neck in the Netherlands between 1993 and 2013 were reviewed.
Results: We identified a total of 77 patients with an osteosarcoma of the head and neck; the 5‐year overall survival (OS) was 55%. In 50 patients with surgically resected high‐ or intermediate‐grade osteosarcoma of the head and neck younger than 75 years, univariate and multivariable analysis, adjusting for age and resection margins, showed that patients who had not received chemotherapy had a significantly higher risk of local recurrence (hazard ratio [HR] = 3.78 and 3.66, respectively).
Conclusion: In patients younger than 75 years of age with surgically resected high‐ and intermediate‐grade osteosarcoma of the head and neck, treatment with (neo‐)adjuvant chemotherapy resulted in a significantly smaller risk of local recurrence. Therefore, we suggest (neo‐)adjuvant chemotherapy in patients amenable to chemotherapy.
Original languageEnglish
Pages (from-to)140-146
Number of pages7
JournalHead and Neck-Journal for the Sciences and Specialties of the Head and Neck
Issue number1
Publication statusPublished - Jan 2017


  • osteosarcoma
  • head and neck neoplasms
  • chemotherapy
  • (neo-)adjuvant
  • mandible
  • maxilla

Cite this